Core Viewpoint - Biomea Fusion, Inc. has announced a public offering of common stock and warrants, aiming to raise approximately $40 million before expenses, with the offering expected to close on June 20, 2025 [1][2]. Group 1: Offering Details - The offering consists of 19,450,000 shares of common stock and accompanying warrants, along with pre-funded warrants for an additional 550,000 shares [1]. - The combined offering price for each share of common stock and accompanying warrant is set at $2.00, while the pre-funded warrant and accompanying warrant are priced at $1.9999 [1]. - Underwriters have a 30-day option to purchase up to an additional 3,000,000 shares and/or warrants at the public offering price [1]. Group 2: Financial Proceeds - The gross proceeds from the offering are expected to be approximately $40 million, excluding any additional shares or warrants purchased by underwriters [2]. - The offering is subject to customary closing conditions and is anticipated to close on June 20, 2025 [2]. Group 3: Management and Regulatory Information - Jefferies is acting as the sole book-running manager for the offering [3]. - The securities are being offered under an effective shelf registration statement previously filed with the SEC [3].

Core Viewpoint - Processa Pharmaceuticals, Inc. has announced a public offering of 28 million shares of common stock at a price of $0.25 per share, aiming to raise approximately $7 million for clinical trials and general corporate purposes [1][2]. Group 1: Offering Details - The public offering includes 28 million shares of common stock or pre-funded warrants, along with common warrants to purchase an additional 28 million shares at an exercise price of $0.25 per share [1]. - The offering is expected to close around June 18, 2025, pending customary closing conditions [1]. - H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering [2]. Group 2: Use of Proceeds - The net proceeds from the offering will be utilized to continue the Phase 2 clinical trial for NCG-Cap, as well as for working capital and general corporate purposes [2]. Group 3: Company Overview - Processa Pharmaceuticals is a clinical-stage pharmaceutical company focused on developing Next Generation Cancer (NGC) therapies that enhance safety and efficacy [5]. - The company's NGC drugs are modifications of existing FDA-approved oncology therapies, aiming to improve the metabolism and distribution of these drugs while retaining their cancer-killing mechanisms [5].

Core Viewpoint - Adial Pharmaceuticals, Inc. has announced a public offering of 11,100,000 shares of common stock and associated warrants, aiming to raise approximately $3.6 million for working capital and general corporate purposes [1][3]. Group 1: Offering Details - The public offering includes Series D warrants to purchase up to 11,100,000 shares and Series E warrants to purchase up to 8,325,000 shares, priced at a combined offering price of $0.3251 per share [1]. - The Series D and Series E warrants will have an exercise price of $0.35 per share, with Series D warrants expiring five years from stockholder approval and Series E warrants expiring eighteen months from stockholder approval [2]. - The closing of the offering is expected on or about June 18, 2025, subject to customary closing conditions [3]. Group 2: Use of Proceeds - The net proceeds from the offering are intended for working capital and general corporate purposes [3]. Group 3: Existing Warrants Amendment - The company will amend existing Series B-1 and Series C-1 warrants to reduce their exercise price from $0.74 to $0.35 per share, subject to stockholder approval [4]. Group 4: Company Overview - Adial Pharmaceuticals is focused on developing therapies for addiction and related disorders, with its lead product AD04 targeting Alcohol Use Disorder (AUD) [7]. - AD04 has shown promising results in a pivotal Phase 3 clinical trial, indicating potential for treating other addictive disorders such as Opioid Use Disorder, gambling, and obesity [7].

Core Viewpoint - Castellum, Inc. has successfully closed a public offering of 4,166,667 Units at a price of $1.20 per Unit, raising approximately $5.0 million in gross proceeds for working capital and general corporate purposes [1][2][3]. Group 1: Offering Details - The public offering consisted of Units, each comprising one share of common stock and one warrant to purchase one share of common stock [1]. - The warrants are immediately exercisable at a price of $1.22 per share and will expire 60 days from the date of issuance [1]. - The shares of common stock and warrants are immediately separable and were issued separately [1]. Group 2: Financial Information - Gross proceeds from the offering are approximately $5.0 million before deducting placement agent fees and offering expenses [2]. - The net proceeds will be utilized for working capital and general corporate purposes [2]. Group 3: Regulatory Information - A shelf registration statement on Form S-3 relating to the securities was previously filed with the U.S. Securities and Exchange Commission (SEC) [3]. - The offering was conducted under a preliminary prospectus supplement and an accompanying prospectus that have been filed with the SEC [4].

Core Viewpoint - Chanson International Holding has announced a public offering expected to generate approximately $8 million in gross proceeds to fund the expansion of its store network in China and the U.S. [1][3] Group 1: Offering Details - The offering consists of 16,000,000 units priced at $0.50 per unit, each unit includes one Class A ordinary share or a pre-funded warrant, along with Series A and Series B warrants [2] - Each Series A and Series B warrant has an exercise price of $0.525 per Class A ordinary share and can be exercised starting from the issuance date until two and a half years later [2] Group 2: Use of Proceeds - The net proceeds from the offering will be allocated to opening new stores in China and the U.S., with specific allocations depending on market conditions [3] Group 3: Company Overview - Chanson International Holding, founded in 2009, operates bakery, seasonal, and beverage products through its chain stores in China and the U.S., with 63 stores in China and 3 in New York City [5] - The company focuses on providing healthy, nutritious, and ready-to-eat food, utilizing advanced facilities and in-depth industry research to meet customer demand [5]

Core Points - Draganfly Inc. announced a public offering of 5,500,000 units at a price of US$2.50 per unit, aiming for gross proceeds of approximately US$13.75 million [1][3] - Each unit consists of one common share and one warrant, with the warrants having an exercise price of CA$5.0768 (or US$3.71) and expiring five years after issuance [1] - The net proceeds from the offering will be used for general corporate purposes, including funding new product capabilities, working capital, acquisitions, and research and development [3] Offering Details - The offering is expected to close on or about June 12, 2025, subject to customary closing conditions [3][4] - Maxim Group LLC is acting as the sole placement agent for the offering [2] - The offering is made under an effective shelf registration statement and a Canadian short form base shelf prospectus [5][6] Company Background - Draganfly Inc. is a pioneer in drone solutions, AI-driven software, and robotics, with over 25 years of innovation in the industry [8] - The company provides solutions for various sectors, including public safety, agriculture, industrial inspections, security, mapping, and surveying [8]

Core Viewpoint - Aduro Clean Technologies Inc. has announced a public offering of 947,868 common shares at a price of US$8.44 per share, aiming to raise approximately US$8 million for research and development, construction of a demonstration-scale plant, and general corporate purposes [1][2]. Group 1: Offering Details - The offering includes 947,868 common shares and accompanying warrants to purchase 473,934 common shares, with each whole warrant exercisable at US$10.13 and expiring three years from issuance [1]. - The offering is managed by D. Boral Capital LLC as the sole book-running manager [2]. - An over-allotment option allows underwriters to purchase an additional 142,180 common shares and/or warrants for 71,090 common shares within 45 days [3]. Group 2: Use of Proceeds - The net proceeds from the offering will be allocated to ongoing research and development costs, expenditures for the construction of a demonstration-scale plant, and any remaining funds for general corporate purposes and working capital [2]. Group 3: Regulatory Information - The offering is conducted under an effective shelf registration statement filed with the U.S. Securities and Exchange Commission (SEC) and a Canadian short form base shelf prospectus [4]. - The base shelf prospectus has been filed with applicable securities commissions in Canada and the SEC, and is available for public access [5]. Group 4: Company Overview - Aduro Clean Technologies specializes in patented water-based technologies for recycling waste plastics, converting heavy crude into lighter oil, and transforming renewable oils into higher-value fuels or chemicals [7]. - The company's Hydrochemolytic™ Technology utilizes water as a key agent in a low-temperature chemistry platform, aiming to convert low-value feedstocks into valuable resources for the 21st century [7].

Core Viewpoint - AirSculpt Technologies, Inc. has announced a public offering of 3,160,000 shares of its common stock, with an additional option for underwriters to purchase up to 474,000 shares [1][2]. Group 1: Offering Details - The public offering consists of 3,160,000 shares of common stock, with a 30-day option for underwriters to buy an additional 474,000 shares [1]. - Vesey Street Capital Partners, the largest stockholder, is interested in purchasing up to $4.0 million in shares from the offering [2]. - Leerink Partners is acting as the sole bookrunner for the offering [3]. Group 2: Use of Proceeds - A portion of the net proceeds from the offering will be used to prepay part of the Company's outstanding debt under its existing credit agreement [3]. - The remaining proceeds will be allocated for general corporate purposes, including working capital and other business opportunities [3]. Group 3: Regulatory Information - A shelf registration statement for the shares was filed with the Securities and Exchange Commission and became effective on March 24, 2025 [4].

Core Viewpoint - Nuwellis, Inc. has announced a public offering of common stock and warrants to raise capital for working and corporate purposes, including potential acquisitions [1][2]. Group 1: Offering Details - The public offering includes 406,755 shares of common stock priced at $0.30 per share, along with pre-funded warrants for 14,085,998 shares priced at $0.2999 each [2]. - Accompanying the common stock are Series A Warrants for up to 43,478,259 shares and Series B Warrants for up to 14,492,753 shares, both with an exercise price of $0.30 [1][3]. - The offering is expected to close on or about June 10, 2025, subject to customary closing conditions [4]. Group 2: Warrant Details - Each pre-funded warrant has an exercise price of $0.0001 and is immediately exercisable until fully exercised [3]. - Series A and Series B Warrants will be exercisable for five years following stockholder approval, with Series A Warrants including a one-time reset of the exercise price under certain conditions [3]. - Series B Warrants offer a zero cash exercise option, allowing holders to receive shares without additional cash payment [3]. Group 3: Company Overview - Nuwellis, Inc. is a commercial-stage medical device company focused on treating fluid overload patients through innovative therapies [7]. - The company is commercializing the Aquadex SmartFlow system, which is designed for ultrafiltration therapy in patients unresponsive to medical management [8]. - Nuwellis is headquartered in Minneapolis and has a wholly owned subsidiary in Ireland [7].

Core Viewpoint - Helius Medical Technologies, Inc. has announced a public offering of 2,768,600 shares of Class A common stock and accompanying warrants, priced at $3.27 per share, aiming to raise approximately $9.1 million in gross proceeds before expenses [1][3]. Group 1: Offering Details - The public offering includes 2,768,600 shares of Class A common stock and warrants to purchase an equal number of shares at a combined price of $3.27 per share [1]. - Each warrant will expire in 2.5 years from issuance, is immediately exercisable at an initial price of $7.3575 per share, and can be exchanged for 2.0 common shares under a zero cash exercise option [2]. - The offering is expected to close on June 6, 2025, subject to customary closing conditions [3]. Group 2: Regulatory and Contact Information - A registration statement on Form S-1 was filed with the SEC and declared effective on June 4, 2025, with a final prospectus to be available on the SEC's website [4]. - Electronic copies of the prospectus can be obtained from Maxim Group LLC, the sole placement agent for the offering [4][7].